Why has GSK's Shingrix vaccine seen a 25% decline in new prescriptions across major US markets since the beginning of this year?

Introduction

The recent 25% decline in new prescriptions for GSK's Shingrix vaccine across major US markets since the beginning of this year is a concerning trend that requires thorough investigation. To address this issue, I'll employ a systematic approach to identify, validate, and address the root cause while considering both immediate and long-term implications for the product's success.

Step 1

Clarifying Questions (3 minutes)

• Given the timing, I'm wondering if there have been any changes in vaccine recommendations. Has the CDC or any other health authority updated their guidelines for Shingrix administration?

Why it matters: Changes in official recommendations could significantly impact prescription rates. Expected answer: No major changes in official guidelines. Impact on approach: If guidelines have changed, we'd need to focus on communication and education strategies.

• Considering the broad market impact, I'm curious about supply chain issues. Have there been any disruptions in vaccine production or distribution that might explain the widespread decline?

Why it matters: Supply constraints could lead to reduced prescriptions across markets. Expected answer: No significant supply chain issues reported. Impact on approach: If supply issues exist, we'd prioritize operational solutions.

• Looking at the competitive landscape, has there been any new entrant or existing competitor making significant moves in the shingles vaccine market?

Why it matters: Competitive pressure could be drawing prescriptions away from Shingrix. Expected answer: No major competitive shifts in the market. Impact on approach: If competition is a factor, we'd need to reassess our market positioning and value proposition.

• Thinking about healthcare provider behavior, have there been any changes in reimbursement policies or insurance coverage for Shingrix that might discourage prescriptions?

Why it matters: Financial incentives play a crucial role in prescription decisions. Expected answer: No significant changes in reimbursement or coverage. Impact on approach: If financial factors are involved, we'd need to address pricing or work with payers on coverage improvements.